Hydroxychloroquine

Healio and Cardiology Today have compiled a list of the top-read news in COVID-19 and CV health.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, highlighted two important studies presented at ACR 2020.

Antimalarial drug shortages due to COVID-19 affected more rheumatology patients in African and East Asian regions than those in the Americas and Europe, noted data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey.

Treatment with hydroxychloroquine does not impact corrected QT length among patients with rheumatoid arthritis or systemic lupus erythematosus, even after adjusting for confounders, according to a speaker at ACR Convergence.

Corrected QT interval was unaffected by hydroxychloroquine use in patients with systemic lupus erythematosus — both with and without chronic kidney disease, according to data presented at the ACR Convergence 2020 virtual meeting.

While guideline-based protocols for hydroxychloroquine dosing adequately protect the majority of individuals, calculations can be “complicated” in vulnerable patients, according to a speaker.

Healio and Cardiology Today have curated a list of our top articles of October in cardiology and cardiac/vascular intervention.

Hydroxychloroquine fails to prevent COVID-19 among adults with rheumatoid arthritis, systemic lupus erythematosus or other related diseases, according to data published in The Lancet Rheumatology.

While the broad range of available therapies to treat rheumatoid arthritis provides clinicians with options, there is still no clear-cut treatment algorithm for every patient, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Rheumatologists treating patients with systemic lupus erythematosus should focus more on hydroxychloroquine blood levels than on prescribed dosage based on weight, according to a speaker at the 2020 Congress of Clinical Rheumatology-West.